Table 1.
Clinicopathological features based distribution of the HNSC, KIRC, LIHC, LUAD, STAD, and UCEC cohorts included in the present study.
| Cancer subtype | Total sample count | Types of the clinicopathological feature | |||
|---|---|---|---|---|---|
| Cancer stages based distribution | Patients ages based distribution | Patients genders based distribution | Geographical distribution | ||
| HNSC | 520 | Stage 1 = 27 | 21–40 years = 20 | Male = 383 | Caucasian = 444 |
| Stage 2 = 71 | 41–60 years = 236 | Female = 136 | African–American = 47 | ||
| Stage 3 = 81 | 61–80 years = 237 | Asian = 11 | |||
| Stage 4 = 264 | 81–100 years = 24 | ||||
| Sample count with missing cancer stages data = 77 | Sample count with missing patients ages data = 3 | Sample count with missing patients genders data = 01 | Sample count with missing geographical data = 02 | ||
| Final sample count undertaken in the analysis = 443 | Final sample count undertaken in the analysis = 517 | Final sample count undertaken in the analysis = 519 | Final sample count undertaken in the analysis = 518 | ||
| KIRC | 533 | Stage 1 = 267 | 21–40 years = 26 | Male = 345 | Caucasian = 462 |
| Stage 2 = 57 | 41–60 years = 238 | Female = 148 | African–American = 56 | ||
| Stage 3 = 123 | 61–80 years = 246 | Asian = 08 | |||
| Stage 4 = 84 | 81–100 years = 23 | ||||
| Sample count with missing cancer stages data = 02 | Sample count with missing patients ages data = 0 | Sample count with missing patients genders data = 0 | Sample count with missing geographical data = 07 | ||
| Final sample count under taken in the analysis = 531 | Final sample count under taken in the analysis = 533 | Final sample count undertaken in the analysis = 533 | Final sample count undertaken in the analysis = 527 | ||
| LIHC | 371 | Stage 1 = 168 | 21–40 years = 27 | Male = 245 | Caucasian = 177 |
| Stage 2 = 84 | 41–60 years = 140 | Female = 117 | African–American = 17 | ||
| Stage 3 = 82 | 61–80 years = 181 | Asian = 157 | |||
| Stage 4 = 06 | 81–100 years = 10 | ||||
| Sample count with missing cancer stages data = 31 | Sample count with missing patients ages data = 13 | Sample count with missing patients genders data = 09 | Sample count with missing geographical data = 20 | ||
| Final sample count under taken in the analysis = 340 | Final sample count under taken in the analysis = 358 | Final sample count undertaken in the analysis = 262 | Final sample count undertaken in the analysis = 351 | ||
| LUAD | 515 | Stage 1 = 277 | 21–40 years = 12 | Male = 238 | Caucasian = 387 |
| Stage 2 = 125 | 41–60 years = 90 | Female = 276 | African–American = 51 | ||
| Stage 3 = 85 | 61–80 years = 149 | Asian = 08 | |||
| Stage 4 = 28 | 81–100 years = 32 | ||||
| Sample count with missing cancer stages data = 0 | Sample count with missing patients ages data = 232 | Sample count with missing patients genders data = 01 | Sample count with missing geographical data = 69 | ||
| Final sample count under taken in the analysis = 515 | Final sample count under taken in the analysis = 283 | Final sample count undertaken in the analysis = 514 | Final sample count undertaken in the analysis = 446 | ||
| STAD | 415 | Stage 1 = 18 | 21–40 years = 04 | Male = 268 | Caucasian = 260 |
| Stage 2 = 123 | 41–60 years = 128 | Female = 147 | African–American = 12 | ||
| Stage 3 = 169 | 61–80 years = 253 | Asian = 87 | |||
| Stage 4 = 41 | 81–100 years = 25 | ||||
| Sample count with missing cancer stages data = 64 | Sample count with missing patients ages data = 05 | Sample count with missing patients genders data = 0 | Sample count with missing geographical data = 56 | ||
| Final sample count under taken in the analysis = 351 | Final sample count under taken in the analysis = 410 | Final sample count undertaken in the analysis = 415 | Final sample count undertaken in the analysis = 359 | ||
| UCEC | 546 | Stage 1 = 341 | 21–40 years = 18 | Male = 268 | Caucasian = 374 |
| Stage 2 = 52 | 41–60 years = 189 | Female = 147 | African–American = 107 | ||
| Stage 3 = 124 | 61–80 years = 292 | Asian = 20 | |||
| Stage 4 = 29 | 81–100 years = 45 | ||||
| Sample count with missing cancer stages data = 0 | Sample count with missing patients ages data = 02 | Sample count with missing patients genders data = 131 | Sample count with missing geographical data = 45 | ||
| Final sample count under taken in the analysis = 546 | Final sample count under taken in the analysis = 544 | Final sample count undertaken in the analysis = 415 | Final sample count undertaken in the analysis = 501 | ||